Cambia (non-profit organization)

Last updated

Cambia
Founded1992
Founder Richard Anthony Jefferson
Type Non-Governmental Organisation with the Food and Agriculture Organization of the United Nations and WIPO. Not-for-profit organisation with the Australian Securities & Investments Commission. [1]
Focus Open innovation, life sciences, intellectual property
Location
Website www.cambia.org

Cambia is an Australian-based global non-profit social enterprise focusing on open science, biology, innovation system reform and intellectual property. Its projects include The Lens, formerly known as Patent Lens, and the Biological Innovation for Open Society Initiative.

Contents

Cambia derives its name from the Spanish verb cambiar, to change. [2]

History

Cambia was established in 1992 by Richard Anthony Jefferson, a leading molecular biologist responsible for the invention of the GUS reporter system, with substantial early participation by Steven G Hughes, Kate J. Wilson, Andrzej Kilian, Chris A. Fields and Sujata Lakhani. Jefferson describes his vision to found a non-profit organisation in Innovations, [3] to provide more efficient and effective tools to solve the problems of agriculture and society.

In 1992, Cambia relocated to Canberra, Australia from The Netherlands, to oversee and troubleshoot the Rockefeller Foundation's rice biotechnology network in Asia. During this time, Jefferson, Wilson and the growing Cambia team visited hundreds of laboratories to help develop, improve, and apply biotechnology capabilities, particularly pertaining to rice. Cambia offered scientific courses and workshops, and increasing assistance in Intellectual Property management. Cambia's ethic was influenced by Jefferson's early years in enabling technology invention and distribution, but greatly refined through increasing awareness of socially and scientifically complex systems and using new thinking about biological evolution (including the Hologenome Theory of Evolution) as models for institution building and collaboration.

Cambia became one of the first social enterprises to use a hybrid licensing model to fund its public good activities. By selectively patenting important technologies, then creating tiered licensing models for their use, Cambia was able to ensure all parties fair access, but larger licensees would be required to pay more for their non-exclusive use, thus subsidising new developments and distribution and support to less wealthy users, including small enterprises and the public sector in the developing world. This model - developed also by the social entrepreneur David Green for universal access to eye care - is now becoming a pillar of social enterprise function.

Over time Cambia's focus moved away from biotechnology and towards innovation systems and Intellectual Property. The Patent Lens and its successor The Lens are now the primary focus of Cambia. Cambia's goal has always been to enable and democratise innovation and their move towards free and open tools that help people understand intellectual property landscapes is a continuation of those values. In this way they have changed from a wet-science research institute into a strategic system-changing social enterprise. In 2012 and 2013, Cambia was rated among the top 100 best NGOs globally by The Global Journal. [4] [5]

Projects

Cambia's work to freely distribute scientific tools and techniques gave rise to the Biological Open Source (BiOS) Initiative in 2005. Through an open-source biotechnology license and Material Transfer Agreement (MTA) developed in 2005–2007, BiOS sought to establish freedom to operate for innovators by providing and exemplifying legal instruments by which innovators could collaboratively use intellectual property protection as a means to share and jointly improve technology for wider utility. BiOS was built on the back of Jefferson's invention of the GUS-based reporter system and the creation of TransBacter, [6] a work-around for the creation of transgenic plants bypassing the highly patented Agrobacterium genus. [7]

Another of Cambia's projects was the development in 2001 [8] by then Chief Scientist Andrzej Kilian of Diversity Arrays Technology, a solid state sequence agnostic genotyping technology that was spun off into a company, DArT, Pty Ltd to perform agricultural genotyping services to the plant breeding community.

A principal current project of Cambia is the free full-text online patent search and exploration facility and knowledge resource, The Lens (previously the Patent Lens). Launched in 2000 with funding from the Rockefeller Foundation as a US agricultural patent search facility, and substantially expanded in 2005–2007 to encompass patent documents from multiple jurisdictions and all domains, and information on the linkages between patent applications and the status of granted patents, the Patent Lens allowed free searching of almost 10 million full-text patent documents. It was distinguished as being the only not-for-profit facility of its kind, with international coverage and integrated links to non-patent literature. The Lens was launched in 2013 as the successor to the Patent Lens, making strides in the visual presentation of patent analysis and workspace management; it is the only global patent site with fully open, shareable, annotatable and re-usable data collections. The Lens now hosts more than 111.5 million patent records and over 60.6 million patent families from over 95 different jurisdictions, including European Patent Office (EPO), United States Patent and Trademark Office (USPTO), IP Australia, World Intellectual Property Organization (WIPO). [9]

The Lens also features an open biological patent facility, PatSeq, led by Professor Osmat Jefferson, [10] with many advanced tools for searching and analysing biological sequences found in patents, to render gene patenting more transparent. The facility has mapped sequences disclosed in gene patents onto the genomes of humans, mice, maize, rice, soybean and others and enable searching at the genome, gene and individual sequence level. The Lens now hosts more than 287 million biological sequences. [11]

In 2017, Professor Osmat Jefferson directed the launching of Lens influence mapping facilities, PatCite and QUT In4M, [12] enabling users to map and measure the influence of scholarly works on invention and innovation. The Lens and its new global In4M Ranking system feature prominently in the Nature Index 2017 Innovation supplement, [13] published in leading science journal Nature [14] and the seminal paper describing the granular metrics and the rankings options was published in the journal Nature Biotechnology. [15] In December 2017, The Lens became more than a patent and sequence facility with the launch of scholarly works search. Initially exposing the scholarly works cited in the patent literature, The Lens now hosts and serves scholarly works from more than 195.5 million scholarly records from multiple sources including Microsoft Academic, Crossref, ORCID, PubMed, Impactstory and CORE. [16]

Governance

Cambia is a social enterprise, and is a registered Non-Governmental Organisation with the Food and Agriculture Organization of the United Nations and a registered observer with the World Intellectual Property Organization. [17] Within Australia, Cambia is registered with the Australian Securities & Investments Commission (ASIC) as a not-for-profit company limited by guarantee.

Cambia's governance is overseen by a Board of Directors, [18] according to its constitution. [19]

Locations

As of July 2012, Cambia operates principally from headquarters in Canberra, ACT, with some staff based in Brisbane, Australia, at the Queensland University of Technology. Before its move to Brisbane in 2008, where it operated for four years, Cambia was located on the Black Mountain research campus of the CSIRO while its glasshouse facilities were housed at the Australian National University campus.

Related Research Articles

<span class="mw-page-title-main">Intellectual property</span> Ownership of creative expressions and processes

Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others. The best-known types are patents, copyrights, trademarks, and trade secrets. The modern concept of intellectual property developed in England in the 17th and 18th centuries. The term "intellectual property" began to be used in the 19th century, though it was not until the late 20th century that intellectual property became commonplace in most of the world's legal systems.

<span class="mw-page-title-main">Patent</span> Type of legal protection for an invention

A patent is a type of intellectual property that gives its owner the legal right to exclude others from making, using, or selling an invention for a limited period of time in exchange for publishing an enabling disclosure of the invention. In most countries, patent rights fall under private law and the patent holder must sue someone infringing the patent in order to enforce their rights.

<span class="mw-page-title-main">World Intellectual Property Organization</span> Specialised agency of the United Nations

The World Intellectual Property Organization is one of the 15 specialized agencies of the United Nations (UN). Pursuant to the 1967 Convention Establishing the World Intellectual Property Organization, WIPO was created to promote and protect intellectual property (IP) across the world by cooperating with countries as well as international organizations. It began operations on 26 April 1970 when the convention entered into force. The current Director General is Singaporean Daren Tang, former head of the Intellectual Property Office of Singapore, who began his term on 1 October 2020.

<span class="mw-page-title-main">Queensland University of Technology</span> Public research university in Brisbane, Australia

The Queensland University of Technology (QUT) is a public research university located in the coastal city of Brisbane in Queensland, Australia. It has two major campuses, a modern city campus in Gardens Point and a historical campus in Kelvin Grove. The university offers courses in fields including architecture, engineering, information technology, healthcare, teaching, law, arts and design, science and mathematics.

<span class="mw-page-title-main">Science and technology in China</span>

Science and technology in China have developed rapidly during the 1980s to 2020s, and major scientific and technological achievements have been made since the 1980s. From the 1980s to the 1990s, the Chinese government successively launched the "863 Plan" and the "Strategy for Rejuvenating the Country through Science and Education", which greatly promoted the development and progress of China's science and technology. The Chinese government has placed emphasis through funding, reform, and societal status on science and technology as a fundamental part of the socio-economic development of the country as well as for national prestige.

As with all utility patents in the United States, a biological patent provides the patent holder with the right to exclude others from making, using, selling, or importing the claimed invention or discovery in biology for a limited period of time - for patents filed after 1998, 20 years from the filing date.

Diamond v. Chakrabarty, 447 U.S. 303 (1980), was a United States Supreme Court case dealing with whether living organisms can be patented. Writing for a five-justice majority, Chief Justice Warren E. Burger held that human-made bacteria could be patented under the patent laws of the United States because such an invention constituted a "manufacture" or "composition of matter". Justice William J. Brennan Jr., along with Justices Byron White, Thurgood Marshall, and Lewis F. Powell Jr., dissented from the Court's ruling, arguing that because Congress had not expressly authorized the patenting of biological organisms, the Court should not extend patent law to cover them.

<span class="mw-page-title-main">Directive on the legal protection of biotechnological inventions</span> European Union directive in the field of patent law

Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions is a European Union directive in the field of patent law, made under the internal market provisions of the Treaty of Rome. It was intended to harmonise the laws of Member States regarding the patentability of biotechnological inventions, including plant varieties and human genes.

BiOS is an international initiative to foster innovation and freedom to operate in the biological sciences. BiOS was officially launched on 10 February 2005 by Cambia, an independent, international non-profit organization dedicated to democratizing innovation. Its intention is to initiate new norms and practices for creating tools for biological innovation, using binding covenants to protect and preserve their usefulness, while allowing diverse business models for the application of these tools.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Traditional knowledge (TK), indigenous knowledge (IK), folk knowledge, and local knowledge generally refer to knowledge systems embedded in the cultural traditions of regional, indigenous, or local communities.

<span class="mw-page-title-main">Richard Anthony Jefferson</span> American molecular biologist

Richard Anthony Jefferson is an American-born molecular biologist and social entrepreneur who developed the widely used reporter gene system GUS, conducted the world's first biotech crop release, proposed the Hologenome theory of evolution, pioneered Biological Open Source and founded The Lens. He is founder of the social enterprise Cambia and a professor of Biological Innovation at the Queensland University of Technology. In 2003 he was named by Scientific American as one of the world's 50 most influential technologists, and is renowned for his work on making science-enabled innovation more widely accessible. He was profiled in 'Open & Shut: The Basement Interviews', and other major media, including in an Economist Feature 'Grassroots Innovator' in 2001.

The Institute on Biotechnology and the Human Future (IBHF) is an affiliate of the Illinois Institute of Technology (IIT) and is housed at IIT's Chicago-Kent College of Law. The IBHF was founded in 2004 by Lori Andrews, J.D., and Nigel M. de S. Cameron, Ph.D., to discuss and analyze the ethical, legal, and social implications of biotechnologies.

Patentleft is the practice of licensing patents for royalty-free use, on the condition that adopters license related improvements they develop under the same terms. Copyleft-style licensors seek "continuous growth of a universally accessible technology commons" from which they, and others, will benefit.

<span class="mw-page-title-main">The Lens</span>

The Lens, formerly called Patent Lens, is a free searcheable online patent and scholarly literature database, provided by Cambia, an Australia-based non-profit organization. The Lens has been hailed as the “most comprehensive scholarly literature database, that exceeds in its width and depth two leading commercial databases combined”. The Lens is an agglomeration database, that takes bibliometric data from other databases and combines them into one, deduplicated and with unified search syntax. Also, unlike the competing databases, The Lens allows data exporting in JSON format with a superior granularity compared to RIS and CSV formats.

<span class="mw-page-title-main">Brian Fitzgerald (academic)</span> Australian legal academic and barrister

Brian Fitzgerald is an Australian legal academic and barrister. He is an intellectual property and information technology/internet lawyer who has pioneered the teaching of internet/cyber law in Australia. Fitzgerald was a specialist research professor at the Queensland University of Technology (QUT) until February 2012, when he became the inaugural executive dean of law at the Australian Catholic University's Faculty of Law and Business.

<span class="mw-page-title-main">Oxford University Innovation</span>

Oxford University Innovation Limited (OUI) is a British technology transfer and consultancy company created to manage the research and development (R&D) of University spin-offs. OUI is a wholly owned subsidiary of the University of Oxford, and is located on Botley Road, Oxford, England. OUI was previously known as Isis Innovation (1988–2016) and Oxford University Research and Development Ltd (1987–1988).

On 29 March 2010, the US District Court for the Southern District of New York found several of the patent claims on the BRCA1 and BRCA2 breast cancer genes held by Myriad Genetics to be invalid. The patents were initially issued on the basis that the genes were isolated and purified to a non-naturally occurring state, however the court found, amongst other things, that the purification was not markedly different from a product of nature and thus was not patentable. The ruling may have implications for holders of other gene patents and the patentability of other naturally occurring substances. It has the potential to directly affect the operation of the healthcare and medical research industries, particularly with regards to cancer treatment and prevention, and may alter the accessibility of such therapies to patients.

A biological patent is a patent on an invention in the field of biology that by law allows the patent holder to exclude others from making, using, selling, or importing the protected invention for a limited period of time. The scope and reach of biological patents vary among jurisdictions, and may include biological technology and products, genetically modified organisms and genetic material. The applicability of patents to substances and processes wholly or partially natural in origin is a subject of debate.

<span class="mw-page-title-main">Clarivate</span> American analytics company

Clarivate Plc is a British-American publicly traded analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business / market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. In the academy and the scientific community, Clarivate is known for being the company that calculates the impact factor, using data from its Web of Science product family, that also includes services/applications such as Publons, EndNote, EndNote Click, and ScholarOne. Its other product families are Cortellis, DRG, CPA Global, Derwent, MarkMonitor, CompuMark, and Darts-ip, and also the various ProQuest products and services.

References

  1. "Cambia's Structure" . Retrieved 6 February 2019.
  2. "Cambiar". 18 August 2021.
  3. Jefferson, Richard (1 October 2006). "Science as Social Enterprise: The CAMBIA BiOS Initiative". Innovations: Technology, Governance, Globalization. 1 (4): 13–44. doi: 10.1162/itgg.2006.1.4.13 . hdl: 2123/2686 . ISSN   1558-2477.
  4. "#86 - Cambia | The Global Journal". theglobaljournal.net. Retrieved 6 February 2019.
  5. "The Top 100 NGOs 2013 | The Global Journal". theglobaljournal.net. Retrieved 6 February 2019.
  6. "TransBacter Project". Archived from the original on 12 February 2019. Retrieved 12 February 2019.
  7. Broothaerts, Wim; Mitchell, Heidi J.; Weir, Brian; Kaines, Sarah; Leon M.A. Smith; Jang, Wei; Mayer, Jorge E.; Roa-Rodriguez, Carolina; Jefferson, Richard A. (10 February 2005). "Gene transfer to plants by diverse species of bacteria". Nature. 433 (7026): 629–633. Bibcode:2005Natur.433..629B. doi:10.1038/nature03309. PMID   15703747. S2CID   4427976.
  8. Jaccoud, D; Peng, K; Feinstein, D; Kilian, A (2001). "Diversity arrays: a solid state technology for sequence information independent genotyping". Nucleic Acids Res. 29 (4): E25. doi:10.1093/nar/29.4.e25. PMC   29632 . PMID   11160945.
  9. "About The Lens". about.lens.org. Retrieved 17 February 2019.
  10. Jefferson, Osmat A; Köllhofer, Deniz; Ehrich, Thomas H; Jefferson, Richard A (2013). "Transparency tools in gene patenting for informing policy and practice". Nature Biotechnology. 31 (12): 1086–1093. doi: 10.1038/nbt.2755 . PMC   7416664 . PMID   24316644.
  11. "The Lens - Free & Open Patent and Scholarly Search". The Lens - Free & Open Patent and Scholarly Search. Retrieved 17 February 2019.
  12. Queensland University of Technology (QUT). "The Lens' open toolkit maps and measures how public research influences innovation". QUT. Retrieved 12 February 2019.
  13. "Nature Index 2017 Innovation | Supplements | Nature Index". www.natureindex.com. Retrieved 12 February 2019.
  14. "A guide to the Nature Index". Nature. 548 (7666): S32. 9 August 2017. Bibcode:2017Natur.548S..32.. doi: 10.1038/548S32a . ISSN   1476-4687. PMID   28792920.
  15. Jefferson, Osmat A.; Jaffe, Adam; Ashton, Doug; Warren, Ben; Koellhofer, Deniz; Dulleck, Uwe; Ballagh, Aaron; Moe, John; DiCuccio, Michael (10 January 2018). "Mapping the global influence of published research on industry and innovation". Nature Biotechnology. 36 (1): 31–39. doi: 10.1038/nbt.4049 . hdl: 1885/311232 . ISSN   1546-1696. PMID   29319684.
  16. "About Lens" . Retrieved 13 February 2019.
  17. "Accredited Observers - International Non-Governmental Organizations". WIPO. Retrieved 29 April 2024.
  18. "Cambia Board of Directors" . Retrieved 12 February 2019.
  19. "Constitution of Cambia" . Retrieved 12 February 2019.